Why PharmEasy bought Thyrocare SUBSCRIBE Thank you for subscribing to Morning Dispatch We'll soon meet in your inbox. / Morning Dispatch PharmEasy, forked out Rs 4,546 crore for a controlling stake in diagnostics firm Thyrocare last week, becoming the first startup unicorn to acquire a listed legacy company in India. We spoke to Siddharth Shah, co-founder and CEO of API Holdings, on why he decided to buy, and to Arokiaswamy Velumani, promoter of Thyrocare, on why he decided to sell. Also in this letter: How Covid changed CEO salaries Google files first report under IT rules ��️ The Rundown by ETtech, our weekly Clubhouse chat show, is back for Season 2!